Patents Examined by Dwayne C. Jones
  • Patent number: RE46129
    Abstract: Caspase activity and apoptosis are promoted using active, dimeric Smac peptide mimetics of the general formula M1-L-M2, wherein moieties M1 and M2 are monomeric Smac mimetics and L is a covalent linker. Target cancerous or inflammatory cells are contacted with an effective amount of an active, dimeric Smac mimetic, and a resultant increase in apoptosis of the target cells is detected. The contacting step may be effected by administering to a pharmaceutical composition comprising a therapeutically effective amount of The compoundic mimetic, wherein the individual may be subject to concurrent or antecedent radiation or chemotherapy for treatment of a neoproliferative pathology.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: August 30, 2016
    Assignee: Board of Regents, The University of Texas System
    Inventors: Patrick G Harran, Xiaodong Wang, Jef K. DeBrabander, Lin Li, Ranny Mathew Thomas, Hidetaka Suzuki
  • Patent number: RE46234
    Abstract: A tissue adhesives and sealant formed by reacting a polyglycerol aldehyde with a water-dispersible, multi-arm amine is described. The tissue adhesive and sealant may be useful for medical and veterinary applications, including, but not limited to, wound closure, supplementing or replacing sutures or staples in internal surgical procedures such as intestinal anastomosis and vascular anastomosis, tissue repair, preventing leakage of fluids such as blood, bile, gastrointestinal fluid and cerebrospinal fluid, ophthalmic procedures, drug delivery, and to prevent post-surgical adhesions.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: December 13, 2016
    Assignee: Actamax Surgical Materials, LLC
    Inventor: Henry Keith Chenault
  • Patent number: RE46424
    Abstract: The present invention describes a method for the synthesis of enantiomerically pure 3-amidinophenylalanine derivatives, which are used as pharmaceutically effective urokinase inhibitors, by starting from 3-cyanophenylalanine derivatives. The methods of manufacture comprising only one synthesis step lead to new intermediates, namely 3-hydroxyamidino- and 3-amidrazonophenylalanine derivatives. These intermediates or their acetyl derivatives can be reduced into the desired 3-amidino-phenylalanine derivatives under gentle conditions (H2 or ammonium formiate formate, Pd/C (approx. 10%), ethanol/water, room temperature, normal pressure or also H2, Pd/C, AcOH or HCl/ethanol, 1-3 bar) in excellent yields and in an enantiomeric excess of up to 99.9%.
    Type: Grant
    Filed: December 31, 2013
    Date of Patent: June 6, 2017
    Assignee: Wilex AG
    Inventors: Hugo Ziegler, Peter Wikstroem
  • Patent number: RE46555
    Abstract: The present invention concerns deuterated catecholamine derivatives as well as pharmaceuticals containing these compounds. In addition, the invention concerns the use of deuterated catecholamine derivatives as well as physiologically acceptable salts thereof, and also pharmaceutical compositions, which contain these compounds, also in combination with enzyme inhibitors, for the treatment of dopamine deficiency diseases or diseases which are based on disrupted tyrosine transport or disrupted tyrosine decarboxylase, as well as other disorders.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: September 19, 2017
    Assignee: Teva Pharmaceuticals International GmbH
    Inventors: Rudolf-Giesbert Alken, Frank Schneider
  • Patent number: RE46617
    Abstract: The present invention relates to the field of synthesizing anti-infective compounds. More particularly, the invention relates to synthesizing a family of quinolone compounds useful as anti-infective agents. The invention includes a process for preparing a quinolone compound wherein less than about 0.40% of dimeric impurity of the quinolone is produced.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: November 28, 2017
    Inventors: Roger Hanselmann, Maxwell M. Reeve, Graham Johnson
  • Patent number: RE46791
    Abstract: The invention relates to substituted dihydroquinazolines and to processes for their preparation and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for use as antiviral agents, in particular against cytomegalo viruses.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: April 17, 2018
    Inventors: Tobias Wunberg, Judith Baumeister, Ulrich Betz, Mario Jeske, Thomas Lampe, Susanne Nikolic, Jurgen Reefschlager, Rudolf Schohe-Loop, Frank Sussmeier, Holger Zimmermann, Rolf Grosser, Kerstin Henninger, Guy Hewlett, Jorg Keldenich, Dieter Lang, Peter Nell
  • Patent number: RE47221
    Abstract: The invention provides compounds of Formula (I) and Formula (II) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: February 5, 2019
    Assignee: AbbVie Inc.
    Inventors: Neil Wishart, Kristine E. Frank, Michael Friedman, Dawn M. George, Kent D. Stewart, Grier A. Wallace
  • Patent number: RE47267
    Abstract: There is disclosed pyridine-and pyrimidinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include pyridine-and pyrimidinecarboxamides compounds. More specifically, there is disclosed a genus of CXCR2 inhibitor compounds that are useful for treating a variety of inflammatory and neoplastic disorders.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: March 5, 2019
    Assignee: Syntrix Biosystems, Inc.
    Inventors: Dean Y. Maeda, John A Zebala
  • Patent number: RE47302
    Abstract: Provided herein are tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (X): and pharmaceutically acceptable salts and compositions including the same. The compounds and compositions provided herein may be used, for example, in the treatment of diseases including inflammation and neurodegenerative disease.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: March 19, 2019
    Inventors: Dustin McMinn, Henry Johnson, Simeon Bowers, David C. Moebius
  • Patent number: RE47451
    Abstract: Provided are a thieno[3,2-d]pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof having inhibitory activity for protein kinase, and a pharmaceutical composition comprising same for prevention and treatment of abnormal cell growth diseases.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: June 25, 2019
    Assignee: Hanmi Pharm. Co. Ltd.
    Inventors: In Hwan Bae, Jung Beom Son, Sang Mi Han, Eun Joo Kwak, Ho Seok Kim, Ji Young Song, Eun Young Byun, Seung Ah Jun, Young Gil Ahn, Kwee Hyun Suh
  • Patent number: RE47475
    Abstract: In preferred embodiments, the present invention provides methods of treatment and pharmaceutical compositions for the suppression, alleviation and prevention of the often chronic, severe and debilitating pain that can accompany inflammatory diseases and neuropathic insults, pain that is often unresponsive to conventional analgesic treatment. The preferred embodiments of the present invention further relate to methods of treatment and pharmaceutical compositions using benzodiazepine derivatives that provide suppression, alleviation and prevention of neuropathic pain, migraine-related pain and inflammatory pain with reduced sedative and ataxic side effects.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: July 2, 2019
    Inventors: James M. Cook, Shengming Huang, Rahul Edwankar, Ojas A. Namjoshi, Zhi-Jian Wang, Qi Huang, Xiaohui He, Xiaoyan Li, Jianming Yu, Dongmei Han
  • Patent number: RE47539
    Abstract: Convenient methods of preparing aza-dibenzocyclooctynes are disclosed herein. Aza-dibenzocyclooctynes attached to a surface are also disclosed herein. Aza-dibenzocyclooctynes can be reacted with azides to form heterocyclic compounds. Such reactions can be useful in a wide variety of applications including, for example, labeling surfaces.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: July 30, 2019
    Inventors: Vladimir V. Popik, Alexander Kuzmin, Andrei Polukhtine
  • Patent number: RE47689
    Abstract: Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy. In a specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN2 into mRNA that is transcribed from the SMN2 gene. In another specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 into mRNA that is transcribed from the SMN1 gene. In yet another embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 and SMN2 into mRNA that is transcribed from the SMN1 and SMN2 genes, respectively.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: November 5, 2019
    Assignees: PTC Therapeutics, Inc., F. Hoffmann-La Roche
    Inventors: Matthew G. Woll, Guangming Chen, Soongyu Choi, Amal Dakka, Song Huang, Gary Mitchell Karp, Chang-Sun Lee, Chunshi Li, Jana Narasimhan, Nikolai Naryshkin, Sergey Paushkin, Hongyan Qi, Anthony A. Turpoff, Marla L. Weetall, Ellen Welch, Tianle Yang, Nanjing Zhang, Xiaoyan Zhang, Xin Zhao, Emmanuel Pinard, Hasane Ratni
  • Patent number: RE47690
    Abstract: The present invention relates to novel hydroxamic acids which are specific histone deacetylase (HDAC) inhibitors and/or TTK/Mps1 kinase inhibitors, including pharmaceutically acceptable salts thereof, which are useful for modulating HDAC and/or TTK/Mps1 kinase activity, pharmaceutical compositions comprising these compounds, and processes for their preparation.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: November 5, 2019
    Assignee: The Regents of the University of Colorado, A Body Corporate
    Inventors: Xuedong Liu, Gan Zhang, Daniel Chuen-Fong Chan, Anthony D. Piscopio
  • Patent number: RE47848
    Abstract: The present invention provides for compounds of Formula I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula all have the meaning as defined herein.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: February 11, 2020
    Assignee: Genentech, Inc.
    Inventors: Anthony Estrada, Alan G. Olivero, Snahel Patel, Michael Siu, Joseph Lyssikatos, Malcolm Huestis, Terry Kellar
  • Patent number: RE47954
    Abstract: ABSTRACT The invention provides combination therapy, wherein one or more other therapeutic agents are administered agents are administered with peptide epoxyketones or a pharmaceutically acceptable salt thereof. Another aspect of the invention relates to treating cancer with a peptide epoxyketone administered in combination with another therapeutic agent.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: April 21, 2020
    Assignee: Onyx Therapeutics, Inc.
    Inventors: Christopher J. Kirk, Susan D. Demo, Mark K. Bennett
  • Patent number: RE48105
    Abstract: The invention relates to compounds of Formula I or a pharmaceutically acceptable salt, ester or prodrug thereof:
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: July 21, 2020
    Assignees: The Broad Institute, Inc., The General Hospital Corporation
    Inventors: Deborah Hung, Sarah Stanley, Tomohiko Kawate, Noriaki Iwase, Motohisa Shimizu
  • Patent number: RE48171
    Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: August 25, 2020
    Assignee: Janssen BioPharma, Inc.
    Inventors: Guangyi Wang, David Bernard Smith, Leonid Beigelman, Jerome Deval, Marija Prhavc
  • Patent number: RE48301
    Abstract: This invention relates to new fused heterocyclic derivatives having affinity to S1P receptors, a pharmaceutical composition containing said compounds, as well as the use of said compounds for the preparation of a medicament for treating, alleviating or preventing diseases and conditions in which any S1P receptor is involved or in which modulation of the endogenous S1P signaling system via any S1P receptor is involved.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: November 10, 2020
    Assignees: AbbVie B.V., AbbVie Inc.
    Inventors: Pieter Smid, Wouter I. Iwema Bakker, Hein K. A. C. Coolen, Leonardus A. J. M. Sliedregt, Maria J. P. van Dongen, Jacobus A. J. den Hartog, Adrian Hobson
  • Patent number: RE48302
    Abstract: Embolic compositions comprising macromers having a backbone comprising a polymeric backbone comprising units with a 1,2-diol or 1,3-diol structure, such as polyvinyl alcohol, and pendant chains bearing crosslinkable groups and, optionally, other modifiers. When crosslinked, the macromers form hydrogels having many properties advantageous for use as embolic agents to block and fill lumens and spaces. The embolic compositions can be used as liquid embolic agents and crosslinked in situ or as preformed embolic articles, such as microspheres.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: November 10, 2020
    Assignee: BioCure, Inc.
    Inventors: Dennis Goupil, Hassan Chaouk, Troy Holland, Bruktawit Asfaw, Stephen D. Goodrich, Lucas Latini